Vocabria

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Cabotegavir sodium, Cabotegravir

Available from:

ViiV Healthcare B.V.

ATC code:

J05AX

INN (International Name):

cabotegravir

Therapeutic group:

Antivirali għal użu sistemiku

Therapeutic area:

Infezzjonijiet ta 'HIV

Therapeutic indications:

Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA.

Product summary:

Revision: 8

Authorization status:

Awtorizzat

Authorization date:

2020-12-17

Patient Information leaflet

                                63
B. FULJETT TA’ TAGĦRIF
64
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
VOCABRIA 400 MG SOSPENSJONI GĦALL-INJEZZJONI LI TERĦI L-MEDIĊINA
BIL-MOD
cabotegravir
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti identifikazzjoni ta’
malajr ta’ informazzjoni ġdida dwar is-sigurtà. Inti tista’
tgħin billi tirrapporta kwalunkwe effett sekondarju li jista’
jkollok. Ara t-tmiem ta’ sezzjoni 4 biex tara kif għandek
tirrapporta effetti sekondarji.
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-infermier
tiegħek.
-
Jekk ikollok xi effett sekondarju, kellem lit-tabib jew lill-infermier
tiegħek. Dan jinkludi xi effett sekondarju
possibbli li mhuwiex elenkat f’dan il-fuljett. Ara sezzjoni 4.
F᾽DAN IL-FULJETT
1.
X’inhu Vocabria u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tingħata Vocabria
3.
Kif jingħataw l-injezzjonijiet ta’ Vocabria
4.
Effetti sekondarji possibbli
5.
Kif taħżen Vocabria
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU VOCABRIA U GĦALXIEX JINTUŻA
L-injezzjoni ta’ Vocabria fiha s-sustanza attiva cabotegravir.
Cabotegravir jappartjeni għal grupp ta’ mediċini
antiretrovirali msejħa
_inibituri tal-integrase (INIs)._
L-injezzjoni ta’ Vocabria tintuża biex tittratta infezzjoni tal-HIV
(virus tal-immunodefiċjenza umana) f’adulti minn
18-il sena ’l fuq, li qed jirċievu wkoll mediċina antiretrovirali
oħra msejħa rilpivirine u li l-infezzjoni HIV-1 tagħha
hija kkontrollata.
_ _
L-injezzjonijiet ta’ Vocabria ma jikkurawx l-infezzjoni tal-HIV;
dawn iżommu l-ammont tal-virus f’ġismek f’livell
baxx. Dan jgħin biex iżżomm in-numru ta’ ċelluli CD4 fid-demm
tiegħek. Iċ-ċelluli CD4 huma tip ta’ ċellula bajda
tad-demm li huma importanti biex jgħinu lill-ġisem tiegħek biex
jiġġieled l-inf
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti identifikazzjoni ta’
malajr ta’ informazzjoni ġdida dwar is-sigurtà. Il-professjonisti
tal-kura tas-saħħa huma mitluba jirrappurtaw
kwalunkwe reazzjoni avversa suspettata. Ara sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
400 mg
Vocabria 400 mg sospensjoni għall-injezzjoni li terħi l-mediċina
bil-mod
600 mg
Vocabria 600 mg sospensjoni għall-injezzjoni li terħi l-mediċina
bil-mod
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
400 mg
Kull kunjett fih 400 mg ta’ cabotegravir f’2 mL.
600 mg
Kull kunjett fih 600 mg ta’ cabotegravir fi 3 mL.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Sospensjoni għall-injezzjoni li terħi l-mediċina bil-mod.
Sospensjoni bajda għal roża ċar.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
L-injezzjoni ta’
_ _
Vocabria, flimkien mal-injezzjoni ta’ rilpivirine, hija indikata
għat-trattament tal-infezzjoni bil-Virus
tal-Immunodefiċjenza Umana tat-tip 1 (HIV-1) f’adulti li huma
soppressi viroloġikament (HIV-1 RNA <50 kopja/mL)
fuq reġimen antiretrovirali stabbli mingħajr evidenza fil-preżent
jew fil-passat ta’ reżistenza virali għal, u l-ebda
falliment viroloġiku minn qabel b’aġenti tal-klassi NNRTI u INI
(ara sezzjonijiet 4.2, 4.4 u 5.1).
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Vocabria għandu jingħata minn tobba esperjenzati fl-immaniġġjar
tal-infezzjoni tal-HIV.
Kull injezzjoni għandha tingħata minn professjonist tal-kura
tas-saħħa.
L-injezzjoni ta’ Vocabria hi indikata għat-trattament tal-HIV-1
flimkien ma’ injezzjoni ta’ rilpivirine, għalhekk, l-
informazzjoni dwar il-preskrizzjoni għall-injezzjoni ta’
rilpivirine għandha tiġi kkonsultata għad-dożaġġ rakkomandat.
QABEL MA TINBEDA L-INJEZZJONI TA’ VOCABRIA, IL-PROFESSJONISTI
TAL-KURA TAS-SAĦĦA GĦANDHOM IKUNU 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-03-2024
Public Assessment Report Public Assessment Report Bulgarian 05-01-2021
Patient Information leaflet Patient Information leaflet Spanish 22-03-2024
Public Assessment Report Public Assessment Report Spanish 05-01-2021
Patient Information leaflet Patient Information leaflet Czech 22-03-2024
Public Assessment Report Public Assessment Report Czech 05-01-2021
Patient Information leaflet Patient Information leaflet Danish 22-03-2024
Public Assessment Report Public Assessment Report Danish 05-01-2021
Patient Information leaflet Patient Information leaflet German 22-03-2024
Public Assessment Report Public Assessment Report German 05-01-2021
Patient Information leaflet Patient Information leaflet Estonian 22-03-2024
Public Assessment Report Public Assessment Report Estonian 05-01-2021
Patient Information leaflet Patient Information leaflet Greek 22-03-2024
Public Assessment Report Public Assessment Report Greek 05-01-2021
Patient Information leaflet Patient Information leaflet English 22-03-2024
Public Assessment Report Public Assessment Report English 05-01-2021
Patient Information leaflet Patient Information leaflet French 22-03-2024
Public Assessment Report Public Assessment Report French 05-01-2021
Patient Information leaflet Patient Information leaflet Italian 22-03-2024
Public Assessment Report Public Assessment Report Italian 05-01-2021
Patient Information leaflet Patient Information leaflet Latvian 22-03-2024
Public Assessment Report Public Assessment Report Latvian 05-01-2021
Patient Information leaflet Patient Information leaflet Lithuanian 22-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-03-2024
Public Assessment Report Public Assessment Report Lithuanian 05-01-2021
Patient Information leaflet Patient Information leaflet Hungarian 22-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 22-03-2024
Public Assessment Report Public Assessment Report Hungarian 05-01-2021
Patient Information leaflet Patient Information leaflet Dutch 22-03-2024
Public Assessment Report Public Assessment Report Dutch 05-01-2021
Patient Information leaflet Patient Information leaflet Polish 22-03-2024
Public Assessment Report Public Assessment Report Polish 05-01-2021
Patient Information leaflet Patient Information leaflet Portuguese 22-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 22-03-2024
Public Assessment Report Public Assessment Report Portuguese 05-01-2021
Patient Information leaflet Patient Information leaflet Romanian 22-03-2024
Public Assessment Report Public Assessment Report Romanian 05-01-2021
Patient Information leaflet Patient Information leaflet Slovak 22-03-2024
Public Assessment Report Public Assessment Report Slovak 05-01-2021
Patient Information leaflet Patient Information leaflet Slovenian 22-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 22-03-2024
Public Assessment Report Public Assessment Report Slovenian 05-01-2021
Patient Information leaflet Patient Information leaflet Finnish 22-03-2024
Public Assessment Report Public Assessment Report Finnish 05-01-2021
Patient Information leaflet Patient Information leaflet Swedish 22-03-2024
Public Assessment Report Public Assessment Report Swedish 05-01-2021
Patient Information leaflet Patient Information leaflet Norwegian 22-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 22-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 22-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 22-03-2024
Patient Information leaflet Patient Information leaflet Croatian 22-03-2024
Public Assessment Report Public Assessment Report Croatian 05-01-2021

Search alerts related to this product

View documents history